INSIGHTS Biotech to Showcase CMC Process Solutions at CSGCT 2025 Following Recent IPO Filing

Suzhou Inscinstech Intelligent Technology Co., Ltd.

Abbreviation: Inscinstech

Booth No.: B11

Inscinstech, founded in 2017, specializes in providing comprehensive solutions for biopharmaceutical CMC (Chemistry, Manufacturing, and Controls), covering upstream and downstream processes as well as laboratory analysis. Leveraging its outstanding innovation capabilities and professional expertise, the company has been honored with numerous accolades, including recognition as a National Specialized and Sophisticated SME, a Suzhou Unicorn Enterprise, a Suzhou Gazelle Enterprise, a Municipal Engineering Research Center, and a High-Tech Enterprise, underscoring its leading position in the industry.

Inscinstech has established two major R&D centers in Suzhou and Beijing, assembling a world-class R&D technical team whose core members hail from top-tier global life sciences instrument companies. The company operates a 10,000+ m² intelligent manufacturing base in Suzhou, ensuring product quality and rapid delivery.

To better serve global customers, Inscinstech has established branch offices in Beijing, Shanghai, Guangzhou, Wuhan, Chengdu, Hangzhou, and other cities, and set up a Global Operations Center in North America. Leveraging its robust sales network and professional technical service team, the company provides efficient and high-quality services to customers worldwide, ensuring rapid response to market demands.

Inscinstech has established collaborations with over 1,200 clients both in China and abroad. Its client base encompasses enterprises, universities, and research institutes in biopharmaceutical-related fields, including antibodies, vaccines, cell and gene therapy (CGT), nucleic acid therapeutics, and in vitro diagnostics (IVD). Furthermore, Inscinstech has forged deep strategic partnerships with key domestic and international clients to jointly drive the development and innovation of the biopharmaceutical industry.

Joining hands to drive the deep integration of cutting-edge technology and industrial resources, co-creating a new blueprint for industry development.

NestoBR is an advanced benchtop bioreactor designed and developed based on bioprocessing principles, intended for process research and development in biopharmaceuticals and biotechnology. Its design meets the high-performance and regulatory requirements of the biopharmaceutical industry, reducing the risk of batch failure in user experiments, enhancing process development capabilities, accelerating life science discoveries, and enabling robust technology transfer.

Product Features:

● Compact structural design

● Rigorous Material Selection and Processing

● Product Design Based on Process Understanding

● Rich High-Performance Hardware Configuration

● Automated Software Architecture

● Compliant with cGMP regulations

● Rapid and Stable Automated Parameter Control

● Comprehensive batch process monitoring and management

● Meets the demands of complex process applications

● Comprehensive Safety Assurance

The new-generation NestoPure chromatography system integrates a sample loading pump and a pH valve, featuring a more compact design that significantly reduces flow path dead volume. The system offers an optional titanium alloy pump head, providing superior corrosion resistance and biocompatibility. Furthermore, the conductivity detector is equipped with a thermally insulated housing, effectively minimizing interference from external temperature fluctuations on conductivity measurements. When paired with the all-new NestoPure SC integrated sampling and collection unit, it enables continuous processing for multi-step chromatography.

The accompanying Unique CDSystem chromatography workstation offers comprehensive functionality and superior performance, integrating instrument control, method management, data analysis, standard curve generation, report editing, user permission management, audit trails, digital signatures, and network database capabilities. This workstation complies with regulatory requirements such as FDA 21 CFR Part 11, GLP, and GMP.

Product Features:

● Equipped with high-precision pumps

● High degree of automation, enabling unattended operation

● Integrated sample loading pump and pH valve for a more compact design

● Optional titanium alloy pump head with enhanced corrosion resistance and biocompatibility

● Optional configurations include various collectors or integrated sample injection and collection systems

● Stylish appearance, more ergonomic, easy to maintain and service

Unique AutoTFF075 is a flexible, automated benchtop tangential flow filtration system that can be paired with hollow fiber cartridges and flat-sheet cassettes for concentration, diafiltration (buffer exchange), purification, and clarification of biologics such as antibodies, recombinant proteins, mRNA, nucleic acids, and viral vectors. Its flexible configuration supports both manual operation and highly automated process control, and, combined with a comprehensive data logging system, it is suitable for small-scale process development, process scale-up studies, and small-batch sample preparation.

Product Features:

● Automatic TMP control, automatic weighing and fluid replenishment, precise control of concentration factor and diafiltration volume

● Compact design with small loop volume and high pump speed to meet the needs for high-fold concentration

● The software features robust functionality, meeting requirements for equipment operation control, data logging, and user management.

● Optional filtrate pump for precise control of filtration rate, meeting the demands of challenging microfiltration processes

● Pre-set common methods, with multiple methods capable of sequential execution for a high degree of automation

● Optional conductivity, pH, and UV monitoring for more comprehensive process control

● Compatible with mainstream membrane cartridges and hollow fibers

To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Cell and Gene Therapy (CSGCT) Conference was established.

Leveraging its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Conference will bring together leading scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions from around the world. The event will showcase the most cutting-edge scientific advances, technologies, applications, and market access information in the global cell and gene therapy field, while facilitating connections between high-quality collaborative projects and overseas investors with investment needs. It aims to build a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global industrial chain.

This conference closely addresses the industry’s hotspots, pain points, and bottlenecks, featuring1 Main Forum + 17 High-End Sub-Forums, coveringLatest Advances in Global Gene Therapy, Immune Cell Therapy, In Vivo CAR-T, Adult Stem Cells and Exosomes, iPSC-Derived Cell Therapies, Oligonucleotide Drugs, Gene Editing, Oncolytic Viruses, and Cancer Vaccines, as well as CMC and Testing, AI-Driven Drug Discovery, Registration and Regulation, Financing and Investment, and Business Development Matchmakingcomprehensive coverage of the entire industry chain.

2025 The 2nd China Cell and Gene Therapy (CSGCT) Conference

September 12-13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, scan the QR code to visit the official conference website.